ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

CAR-T Digest - August 2020

13 Mar 2025: ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

ImmunoPrecise antibodies has partnered with a leading biotech company to develop antibody-drug conjugates and bispecific antibodies for cancer treatment
The collaboration will utilize ImmunoPrecise’s AI-driven discovery platform and B-cell select technology to create highly selective and effective antibody-based therapeutics
The partnership is valued at an initial $8 million, with potential expansion to $10 million, and will last between 18 to 24 months
The goal is to integrate AI to streamline the drug discovery process, accelerating the path from target identification to preclinical candidate selection
ImmunoPrecise has a history of high-profile collaborations, including with BioNTech, and this deal reinforces the growing trend of AI-driven antibody drug development